TELA Bio, Inc.

TELA Bio, Inc. is a commercial-stage medical technology company that provides soft-tissue reconstruction solutions. The company focuses on preserving and restoring a patient's anatomy and leverages the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. TELA Bio's primary product portfolio is the OviTex Reinforced Tissue Matrix ("OviTex"), which was first commercialized in the U.S. in July 2016 and in Europe in February 2019. OviTex addresses needs in hernia repair and abdominal wall reconstruction by combining the benefits of biologic matrices and polymer materials. Hernia repair is a common surgery in the U.S., with approximately 1.2 million procedures annually. The company estimates the annual U.S. total addressable market opportunity for OviTex products to be approximately $1.8 billion, based on the volume-weighted average selling price. The OviTex portfolio includes multiple product configurations for various surgical procedures within hernia repair and abdominal wall reconstruction, such as ventral, inguinal, and hiatal hernia repair. TELA Bio also offers OviTex LPR, an OviTex product designed for laparoscopic and robotic-assisted hernia repair, which began commercialization in November 2018. In February 2023, the company launched two larger configurations of OviTex LPR, specifically for ventral and incisional hernias.